General
Preferred name
ilunocitinib
Synonyms
LY-3411067 ()
LY3411067 ()
P&D ID
PD154939
CAS
1187594-14-4
Tags
available
drug candidate
Drug Status
investigational
Max Phase
1.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Ilunocitinib (compound 27) is a JAK inhibitor (extracted from patent WO2009114512A1)[1].
DESCRIPTION The chemical structure for ilunocitinib was obtained from WHO Proposed list 125. This mapped to PubChem CID 44231134. Ilunocitinib appears to be an oral JAK inhibitor that is intended for veterinary use, and which is being developed by Elanco Animal Health as a therapeutic for inflammatory skin conditions. (GtoPdb)
DESCRIPTION Ilunocitinib is a Janus kinase (JAK) inhibitor (veterinary use). (BOC Sciences Bioactive Compounds)
Compound Sets
5
BOC Sciences Bioactive Compounds
ilunocitinib-cas-1187594-14-4-372999
ChEMBL Drugs
CHEMBL4802241
Guide to Pharmacology
11670
MedChem Express Bioactive Compound Library
HY-132819
PKIDB
External IDs
10
Properties
(calculated by RDKit )
Molecular Weight
383.12
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
5
Aromatic Ring Count
3
cLogP
1.24
TPSA
120.56
Fraction CSP3
0.41
Chiral centers
0.0
Largest ring
6.0
QED
0.71
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
JAK
Pathway
Epigenetics
JAK/STAT Signaling
Protein Tyrosine Kinase/RTK
Stem Cell/Wnt
Source data